Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Disease mechanisms

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Aim This study aims to systematically evaluate and synthesize preclinical evidence on the neuroprotective effects of Triptolide (Tri) in Alzheimer's disease (AD) models, focusing on its impact on amyloid-beta accumulation, synaptic dysfunction, neuroinflammation, oxidative stress, autophagy, and apoptosis. Introduction AD is the most common cause of dementia, yet current treatments largely target symptoms rather than underlying pathology. Tri, a bioactive compound from Tripterygium wilfordii , has shown promise due to its anti-inflammatory, antioxidant, and neuroprotective properties. Methods A systematic search of PubMed, Embase, and Web of Science was conducted up to 16 March 2024. English-language in vivo and in vitro studies on Tri's effects in AD models were included. Methodological quality was assessed using SYRCLE and SciRAP tools. The review is registered in PROSPERO (CRD42024521822). Results Out of 403 studies, 15 met the inclusion criteria (6 in vivo, 8 in vitro, 1 both). Tri reduced Aβ burden, enhanced memory and synaptic integrity, suppressed neuroinflammation and oxidative stress, and modulated autophagy and apoptosis. Conclusion Tri demonstrates significant multi-target neuroprotective effects in AD preclinical models. Further high-quality studies are warranted to optimize dosing, delivery, and safety for clinical translation.

What this study adds

Evidence grade: Low

This is a pooled review. This review of preclinical research found 15 studies, out of 403 screened, testing triptolide, a compound from the plant Tripterygium wilfordii, in Alzheimer's disease models. In these cell and animal models it reduced amyloid-beta build-up, improved memory and synapse health, and dampened inflammation and oxidative stress.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Shami, R., El Majzoub, R., Ismail, A., Kotaich, J., Kassem, M., Safadieh, G., et al. (2026). Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review. Neurodegenerative disease management. https://doi.org/10.1080/17582024.2025.2562776

Vancouver

Shami R, El Majzoub R, Ismail A, Kotaich J, Kassem M, Safadieh G, et al. Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review. Neurodegenerative disease management. 2026. doi:10.1080/17582024.2025.2562776. PMID: 40990233.

BibTeX

@article{shami2026-40990233,
  author  = {Shami, R. and El Majzoub, R. and Ismail, A. and Kotaich, J. and Kassem, M. and Safadieh, G. and Fayyad-Kazan, M. and Chahine, B.},
  title   = {{Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review}},
  journal = {Neurodegenerative disease management},
  year    = {2026},
  doi     = {10.1080/17582024.2025.2562776},
  pmid    = {40990233},
  url     = {https://doi.org/10.1080/17582024.2025.2562776}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This review of preclinical research found 15 studies, out of 403 screened, testing triptolide, a compound from the plant Tripterygium wilfordii, in Alzheimer's disease models. In these cell and animal models it reduced amyloid-beta build-up, improved memory and synapse health, and dampened inflammation and oxidative stress. These are lab results, so the authors call for further high-quality studies on dosing, delivery and safety before it could be tried in patients.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 12 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 42 of 100.42 of 100 points earned58 not earned

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neurodegenerative disease management)
Journal's citation record 0 / 4 Neurodegenerative Disease Management: journal h-index 47 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year 1 / 6 Cited 0.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Bahia Chahine: h-index 9 (OpenAlex, whole career)
Institution's track record 0 / 3 American University of Beirut: institution h-index 404 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40990233)
Free to read 0 / 2 Behind a paywall — scores zero
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Disease mechanisms from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →